恆瑞醫藥 (600276.SS)

39.90 +0.20 (+0.50%) 收市：03:00PM CST

恆瑞醫藥

No. 38, Huanghe Road
Economic and Technological Development Zone
Lianyungang 222000
China

https://www.hrs.com.cn

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 19,611

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Hong Bin Dai	GM & Director	無	無	1976
Mr. Jianjun Liu	Financial Director	無	無	1978
Mr. Jie Ping Sun	Deputy GM & Director	無	無	1970
Dr. Lian Shan Zhang Ph.D.	Deputy GM & Director	無	無	1962
Dr. Ningjun Jiang M.D., Ph.D.	Deputy GM & Director	無	無	1961
Ms. Xiao Han Liu	Secretary of the Board of Directors	無	無	1985
Ms. Su Mei Jiang	Deputy General Manager	無	無	1965
Mr. Ya Ping Shen	Deputy General Manager	無	無	1964
Mr. Cheng Liao	Deputy General Manager	無	無	1975
Mr. Hongsen Wang	Deputy General Manager	無	無	1970

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CNY。

描述

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.

公司管治

截至 2024年6月1日 止，恆瑞醫藥 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：5；董事會：7；股東權利：2；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。